What type of study is this?

This is a Literature Review study.

September 16, 2025Open Access

Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

View Full Paper

Ask AI

Bookmark

Established pharmacotherapies reduce cardiovascular events and slow renal decline, aiding patients with CKM syndrome.
Novel agents targeting specific factors are expanding the therapeutic landscape for better management of CKM.
RNAs and AI show promise in personalizing treatment approaches for CKM, enhancing risk prediction and decision-making.
Integration of clinical trials and mechanistic studies highlights the evolving nature of therapeutic strategies in CKM.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review finds new therapeutic strategies for CKM syndrome, suggesting enhanced outcomes for patients with cardiovascular disease and chronic kidney disease.

Cite This Study

Bharaj et al. (2025) studied this question.

synapsesocial.com/papers/68d4566c31b076d99fa5b951 https://doi.org/10.20944/preprints202507.0009.v2

View Full Paper

Ask AI

Bookmark

Implication

This review finds new therapeutic strategies for CKM syndrome, suggesting enhanced outcomes for patients with cardiovascular disease and chronic kidney disease.

Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

Key Points

Discussion

Implication

Cite This Study

Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider